See Table 1 and 4 legends for expansion of abbreviations and GRADE Working Group grades of evidence. a Patients with acute VTE who had initially received heparin. b Edoxaban 60 mg once daily, or 30 mg once daily if patients with creatinine clearance of 30 to 50 mL/min or a body weight below 60 kg. c CI includes values suggesting no effect and values suggesting either bene t or harm. d Death, with PE not ruled out. Bibliography: Buller et al23 (Hokusai-VTE study) *4. In patients with DVT of the leg or PE who receive extended therapy, we suggest that there is no need to change the choice of anticoagulant after the rst 3 months (Grade 2C). Remarks: It may be appropriate for the choice of anticoagulant to change in response to changes in the patient s circumstances or preferences during the long- term or extended phases of treatment. 